Drug Trial Radar · NCT06938867
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Dec 4, 2024
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- SNIPR Biome Aps.Industry
- Sponsor type
- Industry
- Collaborators
- U.S. Health and Human Services and Biomedical Advanced Research and Development Authority; The European Commission's DG Health Emergency Preparedness and Response Authority (DG HERA) and KfW Development Bank; Italy's Ministry of Economy and Finance; CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator); Wellcome Trust; Novo Nordisk Foundation
- First posted
- Apr 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin. The study consists of two parts. Part 1 will include 24 randomized and dosed patients. Part 2 will be added with amendment 3 and will include 42 randomized and dosed patients. Thus, approximately 66 patients will be randomized 1:1 to oral dosing of SNIPR001 or matching placebo, to be taken concomitantly with SoC levofloxacin prophylaxis. Subjects will be followed until 100 days post allo-HSCT transplant.
Conditions
- E Coli Infections
- Allogenic Transplant Patients
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coliBiological
SNIPR001 is a live biotherapeutic product
Placebo 10 mLOther
Placebo 10 mL matching to SNIPR001 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of SNIPR001 in all patients who receive SNIPR001 or placebo in combination with standard of care (SoC) levofloxacin prophylaxisTime frame: Day 30 and 100 for endpoints 1-7 and 1-2 weeks for endpoint 8
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Not yet recruiting
Weill Cornell Medicine
New York, New York · Recruiting
UPMC
Pittsburgh, Pennsylvania · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.